Dona Ferentes
Did the Thessalonians write back?
- Joined
- 11 January 2016
- Posts
- 20,286
- Reactions
- 28,106
This month's post for the yearly Comp @mullokintyre
last few months came to nought. Jumps around but mainly down -- shorts in control?
CU6 - Clarity Pharmaceuticals
- Thread starter System
- Start date
last few months came to nought. Jumps around but mainly down -- shorts in control?
Dona Ferentes
Did the Thessalonians write back?
- Joined
- 11 January 2016
- Posts
- 20,286
- Reactions
- 28,106
This month's post for the yearly Comp @mullokintyre
Annual report out...
On the 28th of July, Clarity successfully completed a $203 million Placement with a small group of institutional investors who are close to the Company. The issue price of the Placement was $4.20 per share, which represented a 2.2% premium to Clarity’s previous closing price.
“The Placement has received phenomenal support, evidenced by the raising of over $200 million at not only a premium to the last closing share price, but a substantial premium to the share price observed for almost the entirety of CY2025. This places Clarity in a strong position where we can work to complete a number of high value-driving clinical trials, including our pivotal diagnostic Phase III trials, as we progress our products towards potential commercialisation,”
they're probably not too chuffed, losing 25% in the last 6 weeks
maybe the selling pressure is abating
Thorney Technologies (TEK) has 6 per cent of its portfolio in radiopharmaceutical business Clarity Pharmaceuticals..
Alex Waislitz has been liquidating parts of his share portfolio for weeks, with a looming divorce ,.... Thorney and various subsidiaries and related entities have sold down some holdings in many companies
Annual report out...
On the 28th of July, Clarity successfully completed a $203 million Placement with a small group of institutional investors who are close to the Company. The issue price of the Placement was $4.20 per share, which represented a 2.2% premium to Clarity’s previous closing price.
“The Placement has received phenomenal support, evidenced by the raising of over $200 million at not only a premium to the last closing share price, but a substantial premium to the share price observed for almost the entirety of CY2025. This places Clarity in a strong position where we can work to complete a number of high value-driving clinical trials, including our pivotal diagnostic Phase III trials, as we progress our products towards potential commercialisation,”
they're probably not too chuffed, losing 25% in the last 6 weeks
maybe the selling pressure is abating
Thorney Technologies (TEK) has 6 per cent of its portfolio in radiopharmaceutical business Clarity Pharmaceuticals..
Alex Waislitz has been liquidating parts of his share portfolio for weeks, with a looming divorce ,.... Thorney and various subsidiaries and related entities have sold down some holdings in many companies
Last edited:
Dona Ferentes
Did the Thessalonians write back?
- Joined
- 11 January 2016
- Posts
- 20,286
- Reactions
- 28,106
This month's post for the yearly Comp @mullokintyre
.
solid performance for the month, considering.
Annual report to shareholders out on 05 Sept. Lined up for AGM in late Nov
26 Sept 2025
Clarity Pharmaceuticals ,confirms that Clarity’s Targeted Copper Theranostic (TCT) products and clinical development programs will remain unaffected by the United States’ imposed 100% tariff on imports of branded pharmaceutical products that will take effect from 01 October.
Clarity also confirms that all of its isotope and drug product manufacturers for its US clinical trial sites are located in the US. Clarity’s strategy is to target the US market for first approvals of its products with five open Investigational New Drug applications from the US Food and Drug Administration. The registrational Phase III diagnostic trials and Phase I/IIa theranostic trial are located in the US with all products for these US-based trials manufactured and shipped from within the US. By building a supply chain that is fully integrated, from high-volume isotope production, to centralised product manufacture, to delivering these ready-to-use diagnostics to imaging sites in every state of the US on time and on demand, Clarity is aiming to build a model that is impervious to current political dynamics.
.
solid performance for the month, considering.
Annual report to shareholders out on 05 Sept. Lined up for AGM in late Nov
26 Sept 2025
Clarity confirms US-based manufacturing in response to newly announced tariff on pharmaceuticals
Clarity Pharmaceuticals ,confirms that Clarity’s Targeted Copper Theranostic (TCT) products and clinical development programs will remain unaffected by the United States’ imposed 100% tariff on imports of branded pharmaceutical products that will take effect from 01 October.
Clarity also confirms that all of its isotope and drug product manufacturers for its US clinical trial sites are located in the US. Clarity’s strategy is to target the US market for first approvals of its products with five open Investigational New Drug applications from the US Food and Drug Administration. The registrational Phase III diagnostic trials and Phase I/IIa theranostic trial are located in the US with all products for these US-based trials manufactured and shipped from within the US. By building a supply chain that is fully integrated, from high-volume isotope production, to centralised product manufacture, to delivering these ready-to-use diagnostics to imaging sites in every state of the US on time and on demand, Clarity is aiming to build a model that is impervious to current political dynamics.
- Joined
- 13 August 2006
- Posts
- 1,080
- Reactions
- 1,489
As @Dona Ferentes post shows, September wasn't a bad month for CU6.
I'm riding the ups and downs until, hopefully, its trials bear fruit.
@mullokintyre
I'm riding the ups and downs until, hopefully, its trials bear fruit.
@mullokintyre
Dona Ferentes
Did the Thessalonians write back?
- Joined
- 11 January 2016
- Posts
- 20,286
- Reactions
- 28,106
